I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Conditions
Breast - Female
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
- Trial withQuantumLeap Healthcare Collaborative
- Start Date02/02/2022
- End Date12/01/2025
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Anamika Katoch, MD
- Andrea Martelli
- Andrea Silber, MD
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Javin Brita
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kathryn Daniels
- Kerin Adelson, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Lajos Pusztai, MD, DPhil
- Madeline Santiago
- Michael Cohenuram, MD
- Michael DiGiovanna, MD, PhD
- Michelle Corso
- Neal Fischbach, MD
- Pawan Karanam, MD
- Sarah Schellhorn Mougalian, MD
- Su Hsien Lim, MD
- Victor Chang, MD
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated02/03/2022
- Study HIC#2000020575